PureTech Health PLC · LSE:PRTC

PureTech Health — Technical Presentation (February 2026)

16 slides from PureTech Health's technical presentation, February 2026

  1. Slide 1: LYT-200 (Galectin-9 targeting mAb): Supplemental Slides

    LYT-200 (Galectin-9 targeting mAb): Transforming treatment paradigms for hematologic malignancies, such as acute myeloid leukemia (AML) Supplemental Slides

  2. Slide 2: Table of Contents

    Table of Contents  Executive Summary  AML: Aggressive Blood Cancer with Suboptimal Treatment Options  Phase 1b Trial 2

  3. Slide 3: Executive Summary

    bad : BURETECH = o GIVING LIFE TO SCIENCE”

  4. Slide 4: LYT-200: First-in-class Therapy for Acute Myeloid Leukemia (AML)

    LYT-200: First-in-class Therapy for Acute Myeloid Leukemia (AML) Fully human IgG4 monoclonal antibody targeting galectin-9, First-in-class suitable for AML patients regardless of mutation type Gear 1: Direct cell killing by inducing apoptosis/DNA damage Novel Two-Gear MOA Gear 2: Relief of immunosup

  5. Slide 5: LYT-200: A Differentiated Approach

    LYT-200: A Differentiated Approach Clinically De-risked with Clear Unique Mechanism of Action Registrational Path • LYT-200 is a fully human IgG4 antibody • Compelling Phase 1b data targeting galectin-9 • Mutation-agnostic, durable efficacy • Galectin-9 is a foundational regulator of tumor exceeding

  6. Slide 6: Galectin-9 is the Foundational Driver of Leukemia

    Galectin-9 is the Foundational Driver of Leukemia A pro-leukemic protein, key immunosuppressor, and driver of AML microenvironment Overexpressed on AML stem cells but not on normal hematopoietic stem cells1,2 Higher expression in patients for whom frontline therapy and transplant fail2 Key driver of

  7. Slide 7: Unique Two Gear MOA Results in Potent Biological Effect

    Unique Two Gear MOA Results in Potent Biological Effect Challenge • Current therapies predominantly only address Gear 1 or Gear 2 LYT-200 Gear 1 Gear 2 Solution Kills cancer cells Kills cancer cells directly through activation of • Novel therapeutics that address both the immune system Gear 1 and Ge

  8. Slide 8: Acute Myeloid Leukemia (AML): Aggressive Blood Cancer with Suboptimal Treatment Options

    Acute Myeloid Leukemia (AML): Aggressive Blood Cancer with Suboptimal Treatment Options 8

  9. Slide 9: AML is an Aggressive Blood Cancer with Complex Biology, Suboptimal Treatment Options, and No Cure

    AML is an Aggressive Blood Cancer with Complex Biology, Suboptimal Treatment Options, and No Cure Most AML patients become relapsed/refractory to treatment within 1 – 3 years after initial therapy In the first year In 1-3 years ~5.3 mo ~450,000 Median overall survival ~100% >80% in early R/R setting

  10. Slide 10: The AML Journey: Rapid Decline Despite Treatment

    The AML Journey: Rapid Decline Despite Treatment Critical efficacy and safety needs remain even with recent therapeutic advances Patient Journey: Diagnosis to Relapse 1L Tx Transplant R/R AML Stem Cell Median Chemotherapy Ven + HMA Overall Transplant Survival AML Low Dose Following Ven + HMA Diagnos

  11. Slide 11: Phase 1b Trial

    Phase 1b Trial bad : BURETECH = o GIVING LIFE TO SCIENCE” ail

  12. Slide 12: Phase 1b Clinical Trial Design in R/R AML

    Phase 1b Clinical Trial Design in R/R AML 39 patients enrolled in single agent cohort, 62 patients enrolled in combination cohort DOSE FINDING (4+2 DESIGN WITH BACKFILLS) Part 1 Part 2 (Single Agent) (Combination) Cohort 1: 2.0 mg/kg IV QW Cohort 1: 4.0 mg/kg IV QW Expansion at 12 mg/kg of Cohort 2:

  13. Slide 13: Positive Initial Topline Efficacy from Phase 1b Trial in AML/MDS

    Positive Initial Topline Efficacy from Phase 1b Trial in AML/MDS1 LYT-200 shows meaningful response and survival benefits, with data continuing to mature LYT-200 Phase 1b Data3 Proposed Phase 2 Dose KOL-defined Success Benchmark4 12 mg/kg in Combination with Ven/Aza (N=32) Median Progression-free 4.

  14. Slide 14: Majority of VEN/HMA Refractory Patients Achieve Complete Responses on a Combined LYT-200 + VEN/HMA Regimen

    Majority of VEN/HMA Refractory Patients Achieve Complete Responses on a Combined LYT-200 + VEN/HMA Regimen At proposed Phase 2 dose of 12mg/kg, 88% of AML patients were previously treated with VEN/HMA and were either refractory or progressed following an initial response LYT-200 has the potential to

  15. Slide 15: Durable Survival: Patients on LYT-200 and LYT-200 + VEN/HMA live > 2-3x longer

    Durable Survival: Patients on LYT-200 and LYT-200 + VEN/HMA live > 2-3x longer without overlapping toxicity LYT-200 Single LYT-200 + Ven/HMA LYT-200 + Ven/HMA SOC Agent (All doses) (All doses) (Proposed Phase 2 dose) Progression Free Survival (PFS) MONTHS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Overall Sur

  16. Slide 16: Favorable Safety and Tolerability Profile

    Favorable Safety and Tolerability Profile No added toxicity; compatible with VEN/HMA and other R/R and frontline regimens Grade 1 & 2 nausea, diarrhea, rash, pruritus, fatigue, recording as possibly related No overlapping toxicity with VEN/HMA to LYT-200 in <25% of patients LYT-200 Suited for combin

PureTech Health — Technical Presentation (February 2026) on 6ix